In the News
Major media reports on the IMS Institute’s latest forecast for global spending on medicines through 2016. Michael Kleinrock discusses key aspects of the IMS Institute’s report.
American Medical News, June 26, 2012
An examination of health care spending habits conducted by the Kaiser Family Foundation found that health care costs worry even patients with insurance and relatively high incomes. The story cites data from the IMS Institute related to declining physician office visits between 2009 and 2011.
Report by the U.S. House of Representatives, June 15, 2012
The IMS Institute for Healthcare Informatics Report, Drug Shortages: A Closer Look at Products, Suppliers and Volume Volatility, is referenced in this U.S. House of Representatives report on the U.S. drug shortages crisis.
Eye on FDA, May 1, 2012
The issue of drug shortages surfaces periodically in the news and in policy circles, prompting both FDA and Administration officials to various actions. IMS Institute executive director Murray Aitken discusses the U.S. drug shortage issue with Eye on FDA’s Mark Senak.
World Health Care Congress, April 16, 2102
This video features discussion by Murray Aitken about the importance of understanding the spending and utilization patterns for healthcare services among privately insured individuals under age 65 .
National Public Radio, SHOTS Blog, April 5, 2012
The IMS Institute report, The Use of Medicines in the United States: A Review of 2011, provides the context for the NPR SHOTS blog story about a slowdown in spending for prescription medications in the U.S.
PharmExecBlog, April 4, 2012
Provisions of the Affordable Care Act drove out-of pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011. Michael Kleinrock is quoted and a chart that shows changes in prescriptions by patient age are cited throughout this article.
The New York Times, April 4, 2012
Patients cut back on prescription drugs and doctor visits last year, a sign that many Americans are still struggling to pay for healthcare despite economic recovery. Michael Kleinrock discusses the IMS Institute’s analysis of key spending and consumption trends for the U.S. healthcare system.
Bloomberg, April 4, 2012
U.S. senior citizens are filling fewer prescriptions for drugs as out-of-pocket costs rise in a weak economy, undercutting a record level of new product introductions by drug companies. The IMS Institute report, The Use of Medicines in the United States, and quotes by Michael Kleinrock inform reporting for this story.
Bulletin of the World Health Organization, March 14, 2012
Drug shortages are increasingly becoming a global issue. The WHO cites the IMS Institute report, Drug Shortages: A Closer Look at Products, Suppliers and Volume Volatility, as a key reference to this growing issue.
The Los Angeles Times, February 28, 2012
California and other states should consider the medical care used by the highest-cost patients who battle cancer and other chronic conditions when setting essential benefits under federal reform. Dan Malloy comments the impact of high-cost patients for this Los Angeles Times article.
The Huffington Post, February 28, 2012
Health insurance companies are testing ways to provide coverage to the people they can no longer avoid: working-age people with the biggest medical bills. The IMS Institute report helps inform reporting for this story.
Drug Store News, February 28, 2012
Lowering health costs will require a greater understanding of differences between two distinct groups of patients. IMS’s Murray Aitken is quote in this story and data from the report related to pharmacy services is cited.
The New York Times, February 28, 2012
One percent of patients account for more than 25 percent of healthcare spending among the privately insured, with medical bills nearing $100,000. The IMS Institute’s newest report, Spending Among Privately Insured Individuals Under Age 65, and commentary by Dan Malloy is featured.
USAToday, November 29, 2011
Pfizer has devised discounts and incentives for patients, insurers and companies that process Lipitor prescriptions that will, at least for the next six months, give patients access to the brand name drug for about the same cost as generics. Michael Kleinrock comments on Pfizer’s strategy and the benefits Lipitor brings to patients.
National Public Radio: The TakeAway, November 30, 2011
Millions of Americans taking Lipitor will be given a choice to stay on the medication or switch to the generic, as the 20 year patent for the blockbuster prescription drug expires. And Pfizer, the drug’s maker, is moving quickly to keep patients on the name brand. The IMS Institute’s Michael Kleinrock discusses Pfizer’s strategy and the benefits that Lipitor continues to deliver to patients.
Medscape Today News, November 14, 2011
A new report issued by the IMS Institute for Healthcare Informatics shows that 168 drugs are currently in short supply, and most of the shortage clusters around 4 key areas. The report coincided with a presentation here at the American Medical Association (AMA) 2011 Interim Meeting by Bona Benjamin, BS Pharm, director of medication use quality improvement for the American Society of Health-System Pharmacists (ASHP).
GPhA Report, Sep 26, 2011
A study conducted by the IMS Institute for Healthcare Informatics for the Generics Pharmaceutical Association (GPhA) finds that generic versions of brand name drugs helped save the American healthcare system more than $931 Bn over the past decade.
The Washington Times, July 21, 2011
Key findings from the IMS Institute report, Medicare Part D at Age Five: What Has Happened to Seniors’ Prescription Drug Prices?, are cited in this opinion editorial by Manhattan Institute for Policy Research senior fellow and director Paul Howard.
Statement before the Special Committee on Aging of the United States Senate, July 21, 2011
Dr. Scott Gottlieb, resident fellow at the American Enterprise Institute, testifies about the success of the Medicare Part D program, citing key findings from the IMS Institute’s report.
The Hill, July 15, 2011
The Hill reports on the IMS Institute report, Medicare Part D at Age Five: What Has Happened to Seniors’ Prescription Drug Prices?
Reuters, July 15, 2011
The trend toward less costly generic drugs are identified as a key factor that could temper growing costs of the Medicare Part prescription program for seniors and disabled patients.
Managed Care, May 2011
Health plans have many options to improve how they handle these costly therapies. There have been improvements in the underlying medical claims data driving patient adherence research.
PharmExecBlog, May 18, 2011
Estimated growth and the regulatory pathway for biosimilars in the U.S. are outlined.
Bloomberg, May 18, 2011
Bloomberg reports on the IMS Institute for Healthcare Informatics study, The Global Use of Medicines: Outlook through 2015, including extensive commentary on key drivers of future healthcare spending.
The IMS Institute, in its newest study, expects total spending on medicines to exceed $1 trillion over the next five years.
The Chicago Tribune, May 4, 2011
More than $100 billion in annual brand-name drug sales will be at risk for generic competition from 2011 to 2015. That's about one-third of the annual spending on all prescription drugs in the U.S., according to IMS data.
Associated Press, April 19, 2011
The article features insights from the IMS Institute for Healthcare Informatics report, Use of Medicines in the United States: Review of 2010.
The Wall Street Journal Health Blog, April 19, 2011
Key market drivers in 2010, including generic growth and the dynamics around spending and the most widely prescribed products, are outlined, based on the IMS Institute for Healthcare Informatics study, The Use of Medicines in the United States: Review of 2010.
Reuters, April 19, 2011
The IMS Institute for Healthcare Informatics study, Use of Medicines in the United States: Review of 2010, is featured. In the story, Reuters cites the greater use of cheaper generic medicines, less spending on new therapies and fewer patients visiting doctors to begin treatments for chronic illnesses as key factors that contributed to the market's slowing growth.
In its newest study, the IMS Institute reported a 2.3% increase in spending on prescription medicines in the U.S. in 2010.
Washington Business Journal, February 25, 2011
This article reports on the coming “patent cliff” and pharma’s preparedness strategies.
Radio Bulgaria, February 8, 2011
An analysis by IMS related to the demand for and development of medicines in Bulgaria is cited in this news story by Radio Bulgaria.
So Young and So Many Pills: More than 25% of Kids and Teens in the U.S. Take Prescriptions on a Regular Basis
The Wall Street Journal, December 27, 2010
A story on the growing use of chronic medications in children by the Wall Street Journal heavily cites IMS market information.
New York Times, March 17, 2010
Citing IMS’s report on 17 newly-identified pharmerging markets for pharmaceutical industry growth, this article reviews the factors impacting the growth challenges that pharma has faced and steps some companies are taking to capitalize on these markets.